TopoDx

TopoDx is a biotechnology company that has developed an automated AI-driven platform called Cosmos, designed to accelerate clinical microbiology diagnostics. The company's technology utilizes white-light interferometry to measure how bacterial colonies respond to antibiotics at a nanometer scale in real time. By analyzing patient samples directly, the system is engineered to provide pathogen identification and antimicrobial susceptibility testing (AST) results in as little as four hours, significantly faster than traditional methods that typically require three to five days. The company's diagnostic platform is contained within a countertop-sized device intended for use in urgent care facilities and hospitals.

The platform addresses the critical challenge of antimicrobial resistance by enabling faster, more accurate treatment decisions, which can reduce the severity of infections and lower healthcare costs. By automating labor-intensive laboratory processes, TopoDx aims to support understaffed microbiology labs and improve patient outcomes. The company was founded by a team of researchers and business leaders from Georgia Institute of Technology and Emory University, including CEO Yogi Patel, Peter Yunker, and David Weiss. With support from the Emory BioFoundry Institute and other research commercialization programs, TopoDx is currently focused on clinical validation, regulatory pathways for FDA clearance, and real-world pilot deployments.